Larimar Therapeutics
LRMR
89 hedge funds and large institutions have $740M invested in Larimar Therapeutics in 2015 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 48 increasing their positions, 15 reducing their positions, and 20 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 15
101% more call options, than puts
Call options by funds: $2.66M | Put options by funds: $1.32M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
4% less funds holding
Funds holding: 93 → 89 (-4)
16% less capital invested
Capital invested by funds: $881M → $740M (-$141M)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$10.4M |
| 2 |
Jennison Associates
New York
|
+$9.95M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$9.19M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$8.03M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$6.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$94.1M |
| 2 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$34.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$29M |
| 4 |
State Street
Boston,
Massachusetts
|
-$23.4M |
| 5 |
VAM
Visium Asset Management
New York
|
-$8.85M |
LRMR Hedge Fund Activity: Q2 2015 in Review
89 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2015, worth a combined $740M — down 16% from $881M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LRMR and 16 opened new positions — a net loss of 4 holders — while 15 trimmed existing stakes and 48 added.
The largest buyer was Janus Henderson Investors US, adding an estimated $10.4M. The largest seller was Foresite Capital Management II, cutting an estimated $94.1M.
- 89 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2015, down from 93 in Q1 2015.
- Funds reported $740M of Larimar Therapeutics stock for Q2 2015, down 16% quarter-over-quarter.
- 16 funds opened new Larimar Therapeutics positions in Q2 2015 and 20 closed out, a net change of -4 holders.
- The largest Larimar Therapeutics buyer in Q2 2015 was Janus Henderson Investors US, an estimated $10.4M added.
- The largest Larimar Therapeutics seller in Q2 2015 was Foresite Capital Management II, an estimated $94.1M sold.
Based on aggregated 13F filings for Q2 2015.